FreeMind is proud to support the upcoming Investment for Advanced Therapies event! When: May 3, 2017 Where: London, UK Investment for Advanced Therapies will be the C-Level meeting place for heavyweight investors, analysts, biotechs, venture partners and industry experts who are driving the industry forward. Don’t miss your chance to shape the future and put your […]
FreeMind is pleased to support the upcoming MedFIT event! Where: Grenoble, France When: June 28-29, 2017 A 360° approach to build innovation partnerships, source licensing deals and accelerate market access in medtech. Organised by Eurasanté and the NHL Cluster, with the support of Medicalps and Alsace BioValley, the 1st edition of MedFIT will gather […]
The National Institute of Allergies and Infectious Diseases (NIAID) awards close to $6,000,000,000 annually. Taking into account activities by DTRA, DARPA, US Army, BARDA, etc., this is a funding force no one in the field can afford to ignore. In this webinar, we introduce you to Biodefense and Infectious Diseases sources of funding such as […]
The FreeMind Group is proud to support the upcoming BioTrinity conference! Where: London, UK When: May 8-10, 2017 BioTrinity is one of Europe’s leading biopartnering and investment conferences, and the largest of its type in the UK. Now in its 11th year, the aim of BioTrinity is simple – create an ideal networking and partnering platform for life science companies […]
Opening FreeMind’s 2017 webinar series is an introduction to the SBIR and STTR mechanisms which account for over $780,000,000 awarded per year by NIH alone. These are excellent sources of funding aimed at promoting R&D activities of US-based small businesses as well as collaborations with Academics. SBIR/STTRs differ from traditional NIH mechanisms in that they […]
Ram May-Ron of the FreeMind Group opens the 12th Annual Non-Dilutive Funding Summit with a few remarks on recent trends in life science R&D funding and the importance of federal grants as a strategic source of funds.
Dr. Ronald Hann of the Defense Threat Reduction Agency (DTRA) presents the keynote address on Preparing for the Unthinkable. View Slide Deck
Tyler Merkeley of the Biomedical Advanced Research and Development Authority (BARDA) CARB-X program talks about the novel non-dilutive partnership created to promote innovation and foster a robust antimicrobials pipeline. View Slide Deck
Paul McQuade of Greenberg Traurig, LLP shares some legal aspects of federal technology investment and their potential impact on intended markets. View Slide Deck
Dr. Todd Haim of the National Cancer Institute SBIR Development Center describes the NCI’s SBIR and STTR programs, their structure, the Institute’s funding interests, and FAQs. View Slide Deck